Immune and anticancer responses elicited by fully synthetic aberrantly glycosylated MUC1 tripartite vaccines modified by a TLR2 or TLR9 agonist (Q33961477)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Immune and anticancer responses elicited by fully synthetic aberrantly glycosylated MUC1 tripartite vaccines modified by a TLR2 or TLR9 agonist	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Immune and anticancer responses elicited by fully synthetic aberrantly glycosylated MUC1 tripartite vaccines modified by a TLR2 or TLR9 agonist (English)

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

toll-like receptor

0 references

1 reference

based on heuristic

inferred from title

Vani Lakshminarayanan

object named as

Vani Lakshminarayanan

2

0 references

Abu-Baker M Abdel-Aal

object named as

Abu-Baker M Abdel-Aal

1

0 references

Margreet A Wolfert

object named as

Margreet A Wolfert

6

0 references

Geert-Jan Boons

object named as

Geert-Jan Boons

9

0 references

Judy M. Bradley

5

object named as

Judy M Bradley

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

author name string

Pamela Thompson

3

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Nitin Supekar

4

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Peter A Cohen

7

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Sandra J Gendler

8

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

30 May 2014

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

15

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

10

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

1508-1513

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Synthesis and immunological evaluation of a MUC1 glycopeptide incorporated into l-rhamnose displaying liposomes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4113397

5 July 2018

The development of synthetic antitumour vaccines from mucin glycopeptide antigens

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4113397

5 July 2018

TLR2 ligation protects effector T cells from regulatory T-cell mediated suppression and repolarizes T helper responses following MVA-based cancer immunotherapy.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4113397

5 July 2018

Synthesis and immunological evaluation of self-assembling and self-adjuvanting tricomponent glycopeptide cancer-vaccine candidates

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4113397

5 July 2018

A totally synthetic, self-assembling, adjuvant-free MUC1 glycopeptide vaccine for cancer therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4113397

5 July 2018

Intratumoral delivery of CpG-conjugated anti-MUC1 antibody enhances NK cell anti-tumor activity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4113397

5 July 2018

TLR ligand-peptide conjugate vaccines: toward clinical application

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4113397

5 July 2018

Immune recognition of tumor-associated mucin MUC1 is achieved by a fully synthetic aberrantly glycosylated MUC1 tripartite vaccine

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4113397

5 July 2018

Carbohydrate-monophosphoryl lipid a conjugates are fully synthetic self-adjuvanting cancer vaccines eliciting robust immune responses in the mouse

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4113397

5 July 2018

Autoantibodies to aberrantly glycosylated MUC1 in early stage breast cancer are associated with a better prognosis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4113397

5 July 2018

Analysis of a cholera toxin B subunit (CTB) and human mucin 1 (MUC1) conjugate protein in a MUC1-tolerant mouse model

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4113397

5 July 2018

MUC1 immunotherapy.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4113397

5 July 2018

Linear and branched glyco-lipopeptide vaccines follow distinct cross-presentation pathways and generate different magnitudes of antitumor immunity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4113397

5 July 2018

Tumour-associated carbohydrate antigens in breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4113397

5 July 2018

A year of successful cancer vaccines points to a path forward

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4113397

5 July 2018

Identification of O-glycosylated decapeptides within the MUC1 repeat domain as potential MHC class I (A2) binding epitopes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4113397

5 July 2018

Engagement of TLR signaling as adjuvant: towards smarter vaccine and beyond

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4113397

5 July 2018

Targeting of antigens to B cells augments antigen-specific T-cell responses and breaks immune tolerance to tumor-associated antigen MUC1

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4113397

5 July 2018

Mucin-type O-glycosylation and its potential use in drug and vaccine development

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4113397

5 July 2018

Robust immune responses elicited by a fully synthetic three-component vaccine

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4113397

5 July 2018

Distinct uptake mechanisms but similar intracellular processing of two different toll-like receptor ligand-peptide conjugates in dendritic cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4113397

5 July 2018

MUC1-specific immune therapy generates a strong anti-tumor response in a MUC1-tolerant colon cancer model

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4113397

5 July 2018

Therapeutic potential of Toll-like receptor 9 activation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4113397

5 July 2018

O-glycosylated versus non-glycosylated MUC1-derived peptides as potential targets for cytotoxic immunotherapy of carcinoma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4113397

5 July 2018

Antigen-immunostimulatory oligonucleotide conjugates: mechanisms and applications

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4113397

5 July 2018

A human cytotoxic T-lymphocyte epitope and its agonist epitope from the nonvariable number of tandem repeat sequence of MUC-1.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4113397

5 July 2018

DITHIOTHREITOL, A NEW PROTECTIVE REAGENT FOR SH GROUPS

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4113397

5 July 2018

Toll-like receptors and T-helper-1/T-helper-2 responses

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4113397

5 July 2018

A unique molecular chaperone Cosmc required for activity of the mammalian core 1 beta 3-galactosyltransferase

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4113397

5 July 2018

Complex carbohydrates are not removed during processing of glycoproteins by dendritic cells: processing of tumor antigen MUC1 glycopeptides for presentation to major histocompatibility complex class II-restricted T cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4113397

5 July 2018

MUC1-specific cytotoxic T lymphocytes eradicate tumors when adoptively transferred in vivo.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4113397

5 July 2018

MUC1: the polymorphic appearance of a human mucin

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4113397

5 July 2018

Identification of a T-cell epitope adjacent to neutralization antigenic site 1 of poliovirus type 1

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4113397

5 July 2018

Presentation of cytosolic glycosylated peptides by human class I major histocompatibility complex molecules in vivo

1 reference

https://api.crossref.org/works/10.1002%2FCBIC.201402077

21 January 2018

Induction of carbohydrate-specific antibodies in HLA-DR transgenic mice by a synthetic glycopeptide: a potential anti cancer vaccine for human use.

1 reference

https://api.crossref.org/works/10.1002%2FCBIC.201402077

21 January 2018

Novel conjugates of epitope fusion peptides with CpG-ODN display enhanced immunogenicity and HIV recognition.

1 reference

https://api.crossref.org/works/10.1002%2FCBIC.201402077

21 January 2018

Vaccine-induced effector-memory CD8+ T cell responses predict therapeutic efficacy against tumors.

1 reference

https://api.crossref.org/works/10.1002%2FCBIC.201402077

21 January 2018

Mucin 1-specific immunotherapy in a mouse model of spontaneous breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCBIC.201402077

21 January 2018

The immunogenicity of the tumor-associated antigen Lewis(y) may be suppressed by a bifunctional cross-linker required for coupling to a carrier protein

1 reference

https://api.crossref.org/works/10.1002%2FCBIC.201402077

21 January 2018

Survival in early breast cancer patients is favorably influenced by a natural humoral immune response to polymorphic epithelial mucin.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4113397

29 October 2018

Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival

1 reference

https://api.crossref.org/works/10.1002%2FCBIC.201402077

21 January 2018

Analysis of endogenous peptides bound by soluble MHC class I molecules: a novel approach for identifying tumor-specific antigens

1 reference

https://pubmed.ncbi.nlm.nih.gov/24890740

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

O-glycosylated human MUC1 repeats are processed in vitro by immunoproteasomes

1 reference

https://pubmed.ncbi.nlm.nih.gov/24890740

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identification of an HLA-A11-restricted epitope from the tandem repeat domain of the epithelial tumor antigen mucin

1 reference

https://pubmed.ncbi.nlm.nih.gov/24890740

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identification of HLA-A2-restricted T-cell epitopes derived from the MUC1 tumor antigen for broadly applicable vaccine therapies

1 reference

https://pubmed.ncbi.nlm.nih.gov/24890740

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Tolerance and immunity to MUC1 in a human MUC1 transgenic murine model

1 reference

https://pubmed.ncbi.nlm.nih.gov/24890740

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Design of fully synthetic, self-adjuvanting vaccine incorporating the tumor-associated carbohydrate Tn antigen and lipoamino acid-based Toll-like receptor 2 ligand

1 reference

https://pubmed.ncbi.nlm.nih.gov/24890740

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Toll-like receptor agonists and invariant natural killer T-cells enhance antibody-dependent cell-mediated cytotoxicity (ADCC)

1 reference

https://pubmed.ncbi.nlm.nih.gov/24890740

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

TLR1/TLR2 agonist induces tumor regression by reciprocal modulation of effector and regulatory T cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/24890740

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A fully synthetic vaccine consisting of a tumor-associated glycopeptide antigen and a T-cell epitope for the induction of a highly specific humoral immune response

1 reference

https://pubmed.ncbi.nlm.nih.gov/24890740

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1002/CBIC.201402077

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33961477&oldid=1977142562"